{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:01:48Z","timestamp":1790197308507,"version":"4.1.0"},"reference-count":49,"publisher":"American Chemical Society (ACS)","issue":"6","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005195","name":"Office of Public Health Preparedness and Response","doi-asserted-by":"publisher","award":["IDSEP160030"],"award-info":[{"award-number":["IDSEP160030"]}],"id":[{"id":"10.13039\/100005195","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Increasingly resistant Enterobacteriaceae have emerged as a health threat in both hospital and community settings. Infections of the urinary tract, once often treated with oral agents in the community, are requiring increased hospitalization and use of intravenously administered agents for effective treatment. These isolates often carry extended spectrum \u03b2-lactamases (ESBLs) and carbapenemases that necessitate the need for an inhibitor to cover a broad range of \u03b2-lactamases. ETX1317 is a novel diazabicyclooctane class serine \u03b2-lactamase inhibitor that restores the antibacterial activity of several classes of \u03b2-lactams, including third-generation cephalosporins such as cefpodoxime. ETX1317 is currently being developed as an orally available prodrug, ETX0282, to be administered with cefpodoxime proxetil (CPDP). The combination has demonstrated oral efficacy in murine models of infection. Pharmacokinetics established in preclinical species and pharmacokinetic\/pharmacodynamic attributes suggest the orally administered combination ETX0282 + CPDP could serve as an effective treatment option against contemporary ESBL and carbapenemase-producing Enterobacteriaceae.<\/jats:p>","DOI":"10.1021\/acsinfecdis.0c00019","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T12:09:38Z","timestamp":1588853378000},"page":"1378-1388","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacokinetic\/Pharmacodynamic\nDetermination and Preclinical Pharmacokinetics of the \u03b2-Lactamase\nInhibitor ETX1317 and Its Orally Available Prodrug ETX0282"],"prefix":"10.1021","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-8738","authenticated-orcid":true,"given":"John","family":"O\u2019Donnell","sequence":"first","affiliation":[{"name":"Entasis Therapeutics 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Tanudra","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Chen","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hines","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1573-7422","authenticated-orcid":true,"given":"Ruben","family":"Tommasi","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9368-4015","authenticated-orcid":true,"given":"John","family":"Mueller","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics 35 Gatehouse Drive , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"2026090304040285100_cit1","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.amjmed.2006.03.013","article-title":"Resistance\nin Gram-Negative Bacteria: Enterobacteriaceae","volume":"119","author":"Paterson","year":"2006","journal-title":"Am. J. Med."},{"key":"2026090304040285100_cit2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/bmj.h6420","article-title":"Antibiotic resistance in Enterobacteriaceae:\nmechanisms and clinical implications","volume":"2016","author":"Iredell","year":"2016","journal-title":"BMJ."},{"issue":"5","key":"2026090304040285100_cit3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1586\/14787210.6.5.657","article-title":"Multiresistant Enterobacteriaceae:\nnew threat of an old problem","volume":"6","author":"Pitout","year":"2008","journal-title":"Expert Rev. Anti-Infect.\nTher."},{"issue":"2","key":"2026090304040285100_cit4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3201\/eid0702.010239","article-title":"Emerging Mechanisms of Fluoroquinolone Resistance","volume":"7","author":"Hooper","year":"2001","journal-title":"Emerging Infect. Dis."},{"issue":"8","key":"2026090304040285100_cit5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria,\nand role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol."},{"key":"2026090304040285100_cit6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2174\/1874285801206010074","article-title":"Fluoroquinolone resistance\namong gram-negative urinary tract pathogens: global smart program\nresults, 2009\u20132010","volume":"6","author":"Bouchillon","year":"2012","journal-title":"Open Microbiol. J."},{"key":"2026090304040285100_cit7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/976273","article-title":"Global Fluoroquinolone Resistance\nEpidemiology and Implications for Clinical Use","volume":"2012","author":"Dalhoff","year":"2012","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"2026090304040285100_cit8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.amjmed.2008.04.039","article-title":"Emergence\nof fluoroquinolone resistance in outpatient urinary Escherichia coli\nisolates","volume":"121","author":"Johnson","year":"2008","journal-title":"Am. J. Med."},{"key":"2026090304040285100_cit9","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1128\/AAC.00826-13","article-title":"New \u03b2-lactamase inhibitors: a therapeutic renaissance\nin an MDR world","volume":"58","author":"Drawz","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"2026090304040285100_cit10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0025-7125(16)32583-4","article-title":"Ampicillin","volume":"54","author":"Bear","year":"1970","journal-title":"Med. Clin. North Am."},{"issue":"5","key":"2026090304040285100_cit11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1128\/AAC.11.5.780","article-title":"Amoxicillin Therapy\nof Acute Urinary Infections in Adults","volume":"11","author":"Ronald","year":"1977","journal-title":"Antimicrob.\nAgents Chemother."},{"key":"2026090304040285100_cit12","doi-asserted-by":"publisher","first-page":"382S","DOI":"10.1002\/j.1875-9114.1991.tb02649.x","article-title":"Ampicillin-Sulbactam and Ticarcillin-Clavulanic Acid:\nA Comparison of Their In Vitro Activity and Review\nof Their Clinical Efficacy","volume":"11","author":"Itokazu","year":"1991","journal-title":"Pharmacotherapy"},{"issue":"Suppl. S1","key":"2026090304040285100_cit13","doi-asserted-by":"publisher","first-page":"3i","DOI":"10.1093\/jac\/dkh050","article-title":"Augmentin\u00ae (amoxicillin\/clavulanate)\nin the treatment of community-acquired respiratory tract infection:\na review of the continuing development of an innovative antimicrobial\nagent","volume":"53","author":"White","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090304040285100_cit14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1023\/A:1018814627484","article-title":"Intestinal transport of beta-lactam antibiotics: analysis\nof the affinity at the H+\/peptide symporter (PEPT1), the\nuptake into Caco-2 cell monolayers and the transepithelial flux","volume":"16","author":"Bretschneider","year":"1999","journal-title":"Pharm. Res."},{"issue":"3","key":"2026090304040285100_cit15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4103\/0974-777X.68531","article-title":"Extended-spectrum \u03b2-lactamases in Gram Negative Bacteria","volume":"2","author":"Rawat","year":"2010","journal-title":"J. Glob Infect Dis."},{"key":"2026090304040285100_cit16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/625170","article-title":"ESBLs: A Clear\nand Present Danger?","volume":"2012","author":"Rishi","year":"2012","journal-title":"Critical Care Research\nand Practice"},{"issue":"4","key":"2026090304040285100_cit17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"2026090304040285100_cit18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-Avibactam: A Review in\nthe Treatment of Serious Gram-Negative Bacterial Infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"issue":"9","key":"2026090304040285100_cit19","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid \u03b2-Lactamase\nInhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026090304040285100_cit20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4103\/0976-500X.130042","article-title":"Switch over from intravenous\nto oral therapy: A concise overview","volume":"5","author":"Cyriac","year":"2014","journal-title":"J. Pharmacol.\nPharmacother."},{"key":"2026090304040285100_cit21","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00020","article-title":"In vitro Characterization of ETX1317, a novel, broad-spectrum \u03b2-lactamase\ninhibitor that restores and enhances \u03b2-lactam activity against\nmultidrug resistant Enterobacteriaceae, including\ncarbapenem-resistant strains","author":"Miller","year":"2020","journal-title":"ACS Infect. Dis."},{"issue":"Suppl 2","key":"2026090304040285100_cit22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003495-198700342-00008","article-title":"Pharmacokinetic Properties of the\nCephalosporins","volume":"34","author":"Bergan","year":"1987","journal-title":"Drugs"},{"key":"2026090304040285100_cit23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/j.1552-4604.1991.tb03686.x","article-title":"Pharmacokinetic and tolerance studies\nof cefpodoxime after single- and multiple-dose oral administration\nof cefpodoxime proxetil","volume":"31","author":"Borin","year":"1991","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl 3","key":"2026090304040285100_cit24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003495-199100423-00005","article-title":"A review of the pharmacokinetics\nof cefpodoxime proxetil","volume":"42","author":"Borin","year":"1991","journal-title":"Drugs"},{"issue":"1","key":"2026090304040285100_cit25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00019048-199401000-00001","article-title":"Pharmacokinetic and Pharmacodynamic\nConsiderations in Antibiotic Selection, with Particular Attention\nto Oral Cephalosporins","volume":"3","author":"Quintiliani","year":"1994","journal-title":"Infectious Diseases\nin Clinical Practice"},{"issue":"1","key":"2026090304040285100_cit26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1086\/514622","article-title":"The Pharmacodynamics of \u03b2-Lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"2026090304040285100_cit27","volume-title":"M100: Performance Standards for Antimicrobial\nSusceptibility Testing","author":"CLSI.","year":"2018","edition":"28th"},{"key":"2026090304040285100_cit28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-3-0348-9289-6_11","article-title":"In vitro models for the study of antibiotic activities","volume":"31","author":"Blaser","year":"1987","journal-title":"Prog. Drug Res."},{"key":"2026090304040285100_cit29","doi-asserted-by":"publisher","first-page":"e02307","DOI":"10.1128\/AAC.02307-18","article-title":"Generating\nrobust and informative nonclinical in vitro and in vivo bacterial\ninfection model efficacy data to support translation to humans","volume":"63","author":"Bulitta","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"2026090304040285100_cit30","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1086\/518003","article-title":"Impact of Drug-Exposure\nIntensity and Duration of Therapy on the Emergence of Staphylococcus\naureus Resistance to a Quinolone Antimicrobial","volume":"195","author":"Tam","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"S1","key":"2026090304040285100_cit31","doi-asserted-by":"publisher","first-page":"007","DOI":"10.4172\/2167-1052.S1-007","article-title":"The Hollow Fiber Infection Model\nfor Antimicrobial Pharmacodynamics and Pharmacokinetics","volume":"01","author":"Cadwell","year":"2012","journal-title":"Adv. Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"2026090304040285100_cit32","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1128\/AAC.13.4.570","article-title":"New in vitro model to study the effect\nof antibiotic concentration and rate of elimination on antibacterial\nactivity","volume":"13","author":"Grasso","year":"1978","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"2026090304040285100_cit33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1128\/AAC.05005-11","volume":"56","author":"Louie","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090304040285100_cit34","doi-asserted-by":"publisher","first-page":"e02446","DOI":"10.1128\/AAC.02446-17","article-title":"Avibactam pharmacokinetic\/pharmacodynamic targets","volume":"62","author":"Nichols","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"2026090304040285100_cit35","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/jac\/dkv132","article-title":"Pharmacokinetics\/pharmacodynamics\nof a \u03b2-lactam and \u03b2-lactamase inhibitor combination: a\nnovel approach for aztreonam\/avibactam","volume":"70","author":"Singh","year":"2015","journal-title":"J. Antimicrob.\nChemother."},{"issue":"6","key":"2026090304040285100_cit36","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1128\/AAC.02513-12","article-title":"PKPD of tazobactam in combination with ceftolozane\nin an in vitro infection model","volume":"57","author":"VanScoy","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090304040285100_cit37","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1128\/AAC.02747-15","article-title":"Pharmacokinetics-pharmacodynamics\nof tazobactam in combination with piperacillin in an in vitro infection model","volume":"60","author":"Nicasio","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090304040285100_cit38","doi-asserted-by":"publisher","first-page":"e01052","DOI":"10.1128\/AAC.01052-17","article-title":"Pharmacokinetics-pharmacodynamics\nof tazobactam in combination with cefepime in an in vitro infection model","volume":"61","author":"VanScoy","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090304040285100_cit39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1469-0691.2005.01265.x","article-title":"Treatment of infections\nwith ESBL-producing organisms: pharmacokinetic and pharmacodynamic\nconsiderations","volume":"11","author":"Andes","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"2026090304040285100_cit40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ijantimicag.2006.10.006","article-title":"Is all free time above\nthe minimum inhibitory concentration the same: implications for \u03b2-lactam\nin vivo modeling","volume":"29","author":"DeRyke","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"2026090304040285100_cit41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/jac\/dkz414","article-title":"Efficacy of human-simulated bronchopulmonary exposures\nof cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia\nmodel","volume":"75","author":"Kidd","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090304040285100_cit42","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c00579","article-title":"Discovery of ETX0282, an Orally\nAvailable Diazabicycloocta(no)ne Inhibitor of Class A, C and D Serine\n\u03b2-lactamases","author":"Durand-Re\u0301ville","year":"2020","journal-title":"J. Med. Chem."},{"key":"2026090304040285100_cit43","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell, J., Miller, A., Shankaran, H., Ferguson, D., Newman, J., Tommasi, R., and Mueller, J. (2016) Poster 2245. Human Dose Projection of ETX2514\/Sulbactam\nCombination for Use in the Treatment of Infections Caused by Acinetobacter baumannii. IDweek 2016, New\nOrleans, LA.","DOI":"10.1093\/ofid\/ofw172.1793"},{"key":"2026090304040285100_cit44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jcph.793","article-title":"Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of\nAvibactam in Patients with Renal Impairment","volume":"57","author":"Merdjan","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"2026090304040285100_cit45","doi-asserted-by":"publisher","first-page":"e00794","DOI":"10.1128\/AAC.00794-19","article-title":"Pharmacokinetics,\nsafety, and tolerability of intravenous durlobactam and sulbactam\nin subjects with renal impairment and healthy matched control subjects","volume":"63","author":"O\u2019Donnell","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090304040285100_cit46","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3109\/00498254.2011.598582","article-title":"Interspecies\nscaling and prediction of human clearance: Comparison of small and\nmacromolecule drugs","volume":"41","author":"Huh","year":"2011","journal-title":"Xenobiotica"},{"key":"2026090304040285100_cit47","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1124\/dmd.110.037267","article-title":"Prediction of human clearance from\npreclinical species for a diverse set of drugs that exhibit both active\nsecretion and net reabsorption","volume":"39","author":"Paine","year":"2011","journal-title":"Drug Metab.\nDispos."},{"key":"2026090304040285100_cit48","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/infdis\/147.5.910","article-title":"Impact of dosing intervals on activity of gentamycin\nand ticarcillin against Pseudomonas aeruginosa in\nnormal and granulocytopenic mice","volume":"147","author":"Gerber","year":"1983","journal-title":"J. Infect.\nDis."},{"issue":"Suppl. E","key":"2026090304040285100_cit49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/jac\/18.Supplement_E.67","article-title":"The in-vivo postantibiotic effect\nof imipenem and other new antimicrobials","volume":"18","author":"Gudmundsson","year":"1986","journal-title":"J.\nAntimicrob. Chemother."}],"container-title":["ACS Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsinfecdis.0c00019","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/6\/6\/1378\/67183484\/acsinfecdis.0c00019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/6\/6\/1378\/67183484\/acsinfecdis.0c00019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:04:11Z","timestamp":1788422651000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article\/6\/6\/1378\/607845\/Pharmacokinetic-Pharmacodynamic-Determination-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,5,7]]},"published-print":{"date-parts":[[2020,6,12]]}},"URL":"https:\/\/doi.org\/10.1021\/acsinfecdis.0c00019","relation":{},"ISSN":["2373-8227"],"issn-type":[{"value":"2373-8227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]}}}